-
Subject Areas on Research
-
A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder.
-
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
-
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.
-
Age-related declines in exploratory behavior and markers of hippocampal plasticity are attenuated by prenatal choline supplementation in rats.
-
An examination of Alzheimer's disease case definitions using Medicare claims and survey data.
-
Attention-modulating effects of cognitive enhancers.
-
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
-
Characterization of the facilitative effects of perinatal choline supplementation on timing and temporal memory.
-
Chemical knockout of pantothenate kinase reveals the metabolic and genetic program responsible for hepatic coenzyme A homeostasis.
-
Clinical correlates of cognitive decline in vascular dementia.
-
Clinical trials in children with Down syndrome: issues from a cognitive research perspective.
-
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
-
Cognitive enhancers for the treatment of ADHD.
-
Cognitive impairment as a target for pharmacological treatment in schizophrenia.
-
Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats.
-
Comparative cardiovascular safety of dementia medications: a cross-national study.
-
Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.
-
Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
-
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
-
Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.
-
Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging.
-
Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys.
-
Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats.
-
Ethics in everyday pediatrics.
-
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
-
Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
-
H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine.
-
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics.
-
Impact of APOE in mild cognitive impairment.
-
Involvement of dopamine D2 receptors in the suppressive effect of the thyrotropin-releasing hormone analog TA-0910 on alcohol intake in alcohol-preferring rats.
-
Isoflurane prevents learning deficiencies caused by brief hypoxia and hypotension in adult Sprague Dawley rats.
-
Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets.
-
Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes.
-
Lymphomatosis Cerebri: A Diagnostic Challenge.
-
Methods for delivering and evaluating the efficacy of cognitive enhancement.
-
Multi-Trait Analysis of GWAS and Biological Insights Into Cognition: A Response to Hill (2018).
-
Neuroimaging correlates of dementia rating scale performance at baseline and 12-month follow-up among patients with vascular dementia.
-
Neuroinflammation in Alzheimer's disease.
-
Novel insights for systemic inflammation in sepsis and hemorrhage.
-
Oscillatory bands, neuronal synchrony and hippocampal function: implications of the effects of prenatal choline supplementation for sleep-dependent memory consolidation.
-
Poststroke pharmacotherapy: another ictus.
-
Prenatal choline exposure alters hippocampal responsiveness to cholinergic stimulation in adulthood.
-
Prenatal choline supplementation alters the timing, emotion, and memory performance (TEMP) of adult male and female rats as indexed by differential reinforcement of low-rate schedule behavior.
-
Prenatal choline supplementation increases NGF levels in the hippocampus and frontal cortex of young and adult rats.
-
Prenatal dietary choline availability alters postnatal neurotoxic vulnerability in the adult rat.
-
Prenatal-choline supplementation differentially modulates timing of auditory and visual stimuli in aged rats.
-
Progressive morphometric and cognitive changes in vascular dementia.
-
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.
-
Reversal of chlorpyrifos neurobehavioral teratogenicity in mice by nicotine administration and neural stem cell transplantation.
-
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
-
Spatial memory and hippocampal plasticity are differentially sensitive to the availability of choline in adulthood as a function of choline supply in utero.
-
The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
-
The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.
-
Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
-
Thyrotropin releasing hormone analog TA-0910 suppresses alcohol intake in alcohol drinking African green monkeys.
-
Thyrotropin-releasing hormone analog TA-0910 reduces voluntary alcohol intake of P rats subchronically in a limited scheduled access paradigm.
-
Treating cognitive deficits in multiple sclerosis: are we there yet?
-
Keywords of People